Key Takeaways
- Gout is caused by monosodium urate crystal deposition in joints — not by diet alone. Genetics, kidney function, and certain medications are often the bigger drivers.
- The classic presentation is sudden, severe pain in the first metatarsophalangeal joint (big toe), but gout can affect the ankle, knee, wrist, and other joints.
- The 2020 ACR guidelines strongly recommend colchicine at low dose (1.2 mg, then 0.6 mg one hour later) as first-line acute treatment — timing matters more than total dose.
- Allopurinol is the preferred first-line urate-lowering therapy for most patients, including those with chronic kidney disease. The treat-to-target goal is serum uric acid below 6 mg/dL.
- A normal serum uric acid level during an acute flare does not rule out gout. Uric acid redistributes into the joint during inflammation.
- Seek same-day care for a hot, swollen joint with fever — septic arthritis is a medical emergency that can mimic gout and must be excluded quickly.
Gout is the most common inflammatory arthritis in adults, affecting roughly 4% of the U.S. population — over 9 million people.[1] Most patients who come to me with a gout attack say the same thing: they woke up in the middle of the night to pain so intense they couldn't bear the weight of a bed sheet on their foot. That description is nearly diagnostic on its own.
What I find is that gout is simultaneously one of the most undertreated and most misunderstood conditions in primary care. Patients are often told to avoid certain foods and sent home with a pain prescription, without any discussion of why the flare happened, why it will happen again, and what can actually be done to prevent it permanently. This guide covers all of that.
What Is Gout?
Gout is a form of crystal-induced arthritis caused by the deposition of monosodium urate (MSU) crystals in and around joints. It develops when serum uric acid levels remain persistently elevated — a condition called hyperuricemia — long enough for dissolved urate to precipitate into needle-shaped crystals.[2]
Uric acid is the end product of purine metabolism. Purines are natural compounds found in many foods and produced continuously by normal cell turnover in your body. Under normal circumstances, uric acid dissolves in the blood and is excreted by the kidneys. When uric acid production exceeds what the kidneys can eliminate — or when kidney excretion is impaired — levels rise. Above a saturation threshold of approximately 6.8 mg/dL, urate crystals begin to form.
The term podagra refers specifically to gout affecting the first metatarsophalangeal (MTP) joint — the joint at the base of the big toe. This is the classic presentation, occurring in about 56–78% of first gout attacks, because the big toe is the body's most distal and mechanically stressed joint, where temperatures are coolest and urate solubility is lowest.[3]
Gout progresses through distinct phases. The first is asymptomatic hyperuricemia — elevated uric acid with no symptoms. Then comes the acute flare, a sudden and intensely painful inflammatory episode. Between attacks is the intercritical period — the patient feels completely normal, but crystals remain in the joint. Over years without treatment, gout advances to chronic tophaceous gout, where visible crystal deposits (tophi) accumulate under the skin and cause permanent joint damage.
Symptoms of Gout
The Acute Flare
A gout attack typically comes on without warning, often overnight. Pain peaks within 12 to 24 hours and can be genuinely disabling. The affected joint becomes red, swollen, warm to the touch, and exquisitely tender — even light contact with clothing or bed sheets is unbearable for many patients.
Without treatment, most acute flares resolve on their own within 7 to 14 days. The joint returns to normal, and the patient may feel completely well. This apparent recovery is misleading. The crystals remain. Another flare is coming.
Joints Commonly Affected
- First MTP joint (big toe): The classic site. Podagra is so characteristic that experienced clinicians can often diagnose gout on presentation alone.
- Ankle and midfoot: Common, especially in recurrent gout.
- Knee: May present with a large effusion and warmth mimicking septic arthritis.
- Wrist, fingers, and elbow: More common in advanced or polyarticular gout.
- Olecranon bursa: Gout can cause bursitis at the elbow, presenting as a painless or mildly tender fluid-filled sac.
The Intercritical Period
Between flares, patients are typically symptom-free. This is the intercritical period, and it carries a clinical trap: patients feel fine, so they stop their medications. Each successive flare tends to be longer, involves more joints, and takes longer to resolve. Treating gout only during attacks — and ignoring the intercritical period — is the single most common management error I see.
Chronic Tophaceous Gout
Years of untreated or undertreated hyperuricemia lead to tophi — white or yellowish deposits of urate crystals visible under the skin. Tophi appear most often on the ears, fingers, elbows, and Achilles tendon. They are not just cosmetic. Tophi erode bone and cartilage, cause chronic joint inflammation, and can ulcerate through the skin. When I see tophi in a patient, it tells me the disease has been uncontrolled for years.
Causes and Risk Factors
Hyperuricemia arises from overproduction of uric acid, underexcretion by the kidneys, or both. About 90% of patients with gout are underexcretors — their kidneys don't eliminate uric acid efficiently enough. The remaining 10% are overproducers. Identifying which category a patient falls into helps guide treatment selection.
Dietary Factors
Diet contributes to gout, but its role is often overstated. The foods with the strongest evidence for raising uric acid are:
- Organ meats (liver, kidney, sweetbreads): Very high in purines; best avoided entirely.
- Red meat and shellfish: Moderate-to-high purine content. Beef, pork, lamb, shrimp, and lobster all raise uric acid meaningfully.
- Alcohol: Beer has the strongest association — it contains purines from yeast and also inhibits uric acid excretion. Liquor also raises risk. Wine has a weaker association but is not neutral.[1]
- Sugar-sweetened beverages and fructose: High-fructose corn syrup raises uric acid by stimulating purine synthesis. Fructose intake was associated with a 62% increased risk of gout in meta-analysis data.[6]
Diet modifications typically lower serum uric acid by only 1 to 2 mg/dL. For a patient with a uric acid of 9.5 mg/dL, diet alone will not get them to the treatment target. Medications are almost always necessary.
Medications That Raise Uric Acid
- Thiazide diuretics (hydrochlorothiazide, chlorthalidone): Reduce uric acid excretion. The 2020 ACR guidelines conditionally recommend switching hypertensive patients on thiazides to an alternative agent when feasible.[1]
- Loop diuretics (furosemide): Similar mechanism to thiazides.
- Low-dose aspirin (81 mg): Mildly impairs uric acid excretion. However, the ACR guidelines recommend against stopping low-dose aspirin for cardiovascular indications — the cardiac risk outweighs the uric acid effect.
- Cyclosporine and tacrolimus: Used in transplant patients; markedly increase uric acid levels.
- Pyrazinamide and ethambutol: Tuberculosis medications with strong uricosuric-inhibiting effects.
Medical Conditions
- Chronic kidney disease (CKD): Impaired renal uric acid excretion is one of the most common drivers. Gout affects up to 25% of patients with advanced CKD.
- Obesity: Increases uric acid production and reduces excretion. Weight loss is one of the few lifestyle changes with meaningful impact on uric acid levels.
- Hypertension: Associated with reduced renal uric acid clearance.
- Metabolic syndrome and insulin resistance: Insulin impairs renal uric acid excretion.
- Hypothyroidism: Decreases renal urate clearance.
- Psoriasis and myeloproliferative disorders: Increase cell turnover and uric acid production.
Who Gets Gout
Gout is three to four times more common in men than women, primarily because estrogen promotes uric acid excretion in premenopausal women. After menopause, women's gout incidence rises sharply. Age also matters — risk increases significantly after 40 in men and 60 in women. Genetic factors are substantial: variants in genes encoding uric acid transporters (SLC2A9, ABCG2) explain a large portion of hyperuricemia susceptibility.
How Gout Is Diagnosed
The Gold Standard: Joint Aspiration
The definitive diagnosis of gout requires identification of monosodium urate crystals under polarized light microscopy in synovial fluid aspirated from the affected joint. Under polarized light, MSU crystals appear as needle-shaped, negatively birefringent structures — they appear bright yellow when aligned parallel to the slow axis of the compensator.
Joint aspiration is not always performed in straightforward cases, but it serves two critical functions: confirming gout and ruling out septic arthritis, which can present identically and is a true emergency. When there is any doubt, I aspirate.
The 2015 ACR/EULAR Classification Criteria
For clinical practice and research, the 2015 ACR/EULAR classification criteria provide a validated scoring system. The entry criterion is at least one episode of swelling, pain, or tenderness in a peripheral joint or bursa. Finding MSU crystals in synovial fluid is sufficient for classification without further scoring. When crystals are not identified, a point-based system covering clinical features, serum uric acid level, and imaging findings is used.[4] The criteria achieve 92% sensitivity and 89% specificity.
The Serum Uric Acid Caveat
Serum uric acid is useful but unreliable during an acute attack. During an active flare, uric acid redistributes from the bloodstream into the inflamed joint, and blood levels may be normal or even low. A single normal result during a flare does not rule out gout. For an accurate baseline, draw uric acid at least two to four weeks after the acute episode resolves.[4]
Conversely, a serum uric acid below 4 mg/dL makes gout much less likely — this threshold effectively excludes gout under the 2015 classification criteria, since crystals cannot form below the saturation point.
Imaging
Plain X-rays are normal early in gout but may show characteristic "rat-bite" erosions with overhanging edges in chronic disease. Ultrasound can detect a double-contour sign — a hyperechoic line over articular cartilage representing urate deposition — before symptoms develop. Dual-energy CT (DECT) can specifically identify urate deposits and is increasingly used when the diagnosis is uncertain. These imaging findings are incorporated into the 2015 classification criteria.
Treating an Acute Gout Flare
The goal of acute flare treatment is to reduce inflammation and pain as quickly as possible. Three drug classes are effective: colchicine, NSAIDs, and corticosteroids. The 2020 ACR guidelines strongly recommend any of these three as first-line therapy.[1] The choice depends on the patient's comorbidities, kidney function, and what they can tolerate.
The earlier treatment begins after the onset of a gout flare, the more effective it is. Starting colchicine within 12–24 hours of flare onset produces dramatically better outcomes than starting it after 48 hours. What I tell every patient is this: keep your colchicine at home, and take it at the first sign of a flare — don't wait to call the office.
Colchicine — The First Choice When Started Early
The AGREE trial established that low-dose colchicine is as effective as high-dose colchicine with a side effect profile essentially indistinguishable from placebo.[3] This was a landmark finding. The old regimen — colchicine every hour until diarrhea occurs — has been replaced.
ACR 2020 recommended dosing: 1.2 mg at the first sign of a flare, followed by 0.6 mg one hour later (total 1.8 mg on day one). If the flare continues, 0.6 mg once or twice daily can be continued for several days.[1]
Colchicine requires dose reduction in moderate kidney disease and is contraindicated with certain drugs (strong CYP3A4 inhibitors like clarithromycin significantly increase colchicine levels to toxic range). Always check for interactions before prescribing.
NSAIDs
NSAIDs are highly effective for acute gout and work best when started at full anti-inflammatory doses early. Indomethacin (50 mg three times daily) and naproxen (500 mg twice daily) are the most commonly used agents. Ibuprofen at adequate doses (600–800 mg three times daily) is also appropriate.
NSAIDs should be used cautiously or avoided in patients with peptic ulcer disease, heart failure, or significant CKD (GFR below 30 mL/min). For patients on anticoagulants, the bleeding risk warrants consideration.
Corticosteroids
Oral prednisone (30–40 mg daily for 3–5 days, then taper) is equally effective to NSAIDs and is often my first choice in patients with CKD, heart failure, or who cannot tolerate colchicine or NSAIDs. Intraarticular corticosteroid injection is particularly effective for a single accessible joint — it delivers a high local concentration with minimal systemic exposure.
For patients who cannot take oral medications, intramuscular or intravenous methylprednisolone is an option. IL-1 inhibitors (anakinra, canakinumab) are available for refractory cases but are not first-line.
| Treatment | Typical Dose | Best For | Key Cautions |
|---|---|---|---|
| Colchicine | 1.2 mg, then 0.6 mg 1 hr later; continue 0.6 mg BID | Flare <36 hours onset; prophylaxis; no CKD | Reduce dose in CKD; drug interactions (clarithromycin) |
| NSAIDs (indomethacin, naproxen) | Indomethacin 50 mg TID; naproxen 500 mg BID | Good renal function; no GI/cardiac contraindications | Avoid in CKD <30 mL/min, CHF, active PUD |
| Prednisone (oral) | 30–40 mg/day × 3–5 days, taper 5–7 days | CKD; anticoagulated patients; multiple joints | Monitor blood glucose in diabetics; risk of rebound if tapered too fast |
| Intraarticular corticosteroid | Triamcinolone 10–40 mg per joint (size-dependent) | Single accessible joint; unable to tolerate systemic therapy | Exclude septic arthritis first; aseptic technique required |
Long-Term Management: Urate-Lowering Therapy
Treating flares without addressing the underlying hyperuricemia is the clinical equivalent of mopping up water without turning off the faucet. Urate-lowering therapy (ULT) is the mechanism by which gout can be cured — or at least driven into permanent remission.
When to Start ULT
The 2020 ACR guidelines strongly recommend initiating ULT for patients with any of the following: two or more flares per year, tophaceous gout, radiographic damage attributable to gout, or urolithiasis (kidney stones from uric acid).[1] ULT is also conditionally recommended for patients with CKD stage 3 or higher or serum uric acid above 9 mg/dL, even with infrequent flares.
A first-ever flare with no comorbidities? The 2020 ACR guidelines conditionally recommend against starting ULT immediately after a single first flare — the decision depends on several factors. I review each case individually. A 30-year-old with a uric acid of 10 mg/dL and a family history of tophaceous gout gets a different conversation than a 70-year-old with a first mild attack and normal labs.
Can ULT Be Started During a Flare?
Yes, and this practice has gained support. The 2020 ACR guidelines conditionally recommend starting ULT during an acute flare when indicated, rather than waiting for resolution.[1] The traditional concern — that starting allopurinol during a flare prolongs or worsens it — has not been confirmed in clinical studies. A 2021 study found no significant difference in flare duration or resolution time between early and late allopurinol initiation.[7] The practical benefit is that patients who come to me in a flare are highly motivated to start long-term treatment — that motivation should be used, not wasted.
When starting ULT during a flare, anti-inflammatory prophylaxis (colchicine 0.6 mg daily) should be continued concurrently for at least 3–6 months to prevent flare mobilization from the initial uric acid drop.
Allopurinol — The Preferred First-Line ULT
Allopurinol is a xanthine oxidase inhibitor that blocks the enzyme responsible for the final step in uric acid synthesis. The 2020 ACR guidelines strongly recommend allopurinol as the preferred first-line ULT for all patients, including those with CKD stage 3 or higher — a shift from older guidance that favored febuxostat in CKD.[1]
Dosing approach: Start low (100 mg daily; 50 mg daily in CKD), then titrate upward every 2–5 weeks based on serum uric acid. Do not start at 300 mg — abrupt high-dose initiation increases the risk of mobilization flares. The maximum approved dose is 800 mg daily, though most patients achieve target at 300–400 mg.
HLA-B*5801 testing before allopurinol initiation is recommended in Han Chinese, Korean, and Thai patients, who carry a genetic variant associated with severe allopurinol hypersensitivity syndrome. This is a potentially fatal reaction involving skin blistering, organ failure, and high mortality.
Febuxostat — When Allopurinol Isn't Right
Febuxostat (Uloric) is a non-purine selective xanthine oxidase inhibitor with stronger uric acid-lowering efficacy than standard allopurinol doses. It is used when allopurinol is contraindicated or not tolerated.
The FAST trial (2020, Lancet) found febuxostat was non-inferior to allopurinol for major adverse cardiovascular events in gout patients.[5] However, an earlier FDA-mandated trial (CARES) showed higher all-cause and cardiovascular mortality with febuxostat versus allopurinol in patients with established cardiovascular disease — a signal that led to an FDA black box warning. The ACR 2020 guidelines recommend caution with febuxostat in patients with established cardiovascular disease and suggest using allopurinol when possible in that population.
The Treat-to-Target Strategy
The 2020 ACR guidelines strongly recommend a treat-to-target approach: adjust ULT dose until serum uric acid is durably below 6 mg/dL.[2] This is the threshold below which urate crystals dissolve back into solution and tophi shrink.
For patients with tophaceous gout, some experts target below 5 mg/dL to accelerate crystal dissolution. Fixed-dose strategies — giving 300 mg of allopurinol and never adjusting — are no longer acceptable practice. Serial uric acid monitoring every 2–5 weeks during titration is standard, then annually once stable.
Gout vs. Other Joint Conditions
| Condition | Key Distinguishing Features | How to Differentiate |
|---|---|---|
| Pseudogout (CPPD) | Calcium pyrophosphate crystals; often affects the knee or wrist in older adults; positively birefringent crystals on microscopy (rhomboid shape) | Joint aspiration — CPPD crystals vs. MSU crystals; chondrocalcinosis on X-ray |
| Septic arthritis | Can be identical in presentation; fever common; WBC >50,000 in synovial fluid raises concern; does not spontaneously resolve | Joint aspiration with Gram stain and culture — must be excluded before treating as gout alone |
| Rheumatoid arthritis | Symmetric small joint involvement; morning stiffness lasting >60 minutes; RF and anti-CCP antibodies; chronic rather than episodic | Serology, pattern of involvement, synovial biopsy in unclear cases |
| Reactive arthritis | Typically follows GI or urogenital infection; often accompanies urethritis, conjunctivitis, or skin lesions; asymmetric lower extremity joints | Clinical history; cultures; negative for MSU crystals |
| Cellulitis | Skin infection without joint involvement; may spread beyond joint; no effusion on aspiration; responds to antibiotics | No synovial fluid; skin origin of inflammation; MRI if uncertain |
Septic arthritis deserves special emphasis. It can look exactly like a gout flare — red, hot, swollen joint with severe pain. Missing septic arthritis means missing a joint-destroying, potentially life-threatening infection. When fever is present with an acute monoarthritis, joint aspiration is not optional.
Diet and Lifestyle: What Actually Matters
Dietary advice for gout is often oversimplified. I want to give you accurate expectations rather than false promises.
What Clearly Matters
- Alcohol: Beer and liquor raise uric acid meaningfully. Beer in particular — both through purine content and by impairing uric acid excretion. If you have active gout or are trying to reach your uric acid target, alcohol reduction is one of the highest-impact dietary changes you can make.
- Sugar-sweetened beverages: High-fructose corn syrup drives uric acid production. Soda and sweetened juices are worth eliminating entirely.
- Organ meats: Liver, kidney, and sweetbreads have very high purine loads. Avoid them.
- Weight loss: Even modest weight loss improves uric acid levels and reduces flare frequency. The 2020 ACR guidelines conditionally recommend weight loss for all overweight or obese patients with gout, regardless of disease activity.[1]
- Hydration: Good fluid intake supports renal uric acid excretion. Coffee (regular or decaf) has an inverse association with gout risk — it appears to improve uric acid clearance.
The Myths Worth Addressing
Many patients avoid vegetables entirely because they read that spinach, mushrooms, and lentils are high in purines. Plant-based purines do not behave like animal purines — they have little to no impact on serum uric acid or gout flare risk. Low-fat dairy may actually be protective. Cherry consumption has modest evidence of benefit — the 2020 ACR guidelines conditionally recommend it as part of dietary management.
Vitamin C supplements are commonly recommended online. The 2020 ACR guidelines conditionally recommend against vitamin C supplementation for gout management — the evidence does not support it. Save the money.
Diet changes alone typically lower serum uric acid by 1–2 mg/dL. For a patient with a uric acid of 9 mg/dL, diet modification brings them to perhaps 7.5 mg/dL — still above the 6 mg/dL target. This is why diet and lifestyle are adjuncts to medication, not replacements for it.
When to See a Doctor: A Decision Framework
| Situation | Recommended Action |
|---|---|
| First episode of acute joint pain, swelling, or redness — not previously diagnosed | See a physician within 24–48 hours to confirm diagnosis and rule out septic arthritis |
| Known gout flare with no fever, manageable pain, and colchicine or NSAID at home | Treat at home; contact physician if not improving within 3–5 days |
| Gout flare with fever (above 100.4°F / 38°C) | Same-day urgent evaluation — fever with monoarthritis requires joint aspiration to exclude septic arthritis |
| No prior gout diagnosis; uric acid above 9 mg/dL found incidentally | Discuss ULT initiation with your physician — risk-benefit assessment is warranted even without prior flares |
| Multiple flares per year despite lifestyle changes | Initiate or optimize urate-lowering therapy; refer to rheumatology if target uric acid not achieved |
| Visible tophi, joint deformity, or chronic joint pain | Rheumatology referral for advanced gout management and possible pegloticase consideration |
Red Flags: When Gout Becomes an Emergency
- Fever with joint swelling — this combination requires same-day evaluation. Septic arthritis is a medical emergency. Delayed treatment leads to irreversible joint destruction and can be fatal in immunocompromised patients.
- Rapidly spreading redness beyond the joint — may indicate necrotizing fasciitis or cellulitis requiring immediate surgical or IV antibiotic intervention.
- Multiple hot joints simultaneously in a patient with fever — polyarticular septic arthritis or bacterial endocarditis should be considered.
- Tophus ulceration with drainage — open tophi are at high risk of secondary bacterial infection and require prompt wound care and antibiotic coverage.
- Acute kidney injury — severe hyperuricemia can precipitate in renal tubules, causing acute obstructive nephropathy (tumor lysis syndrome in cancer patients; rarely in severe untreated gout). Flank pain with rising creatinine warrants urgent evaluation.
Tophaceous Gout Complications
Chronic tophaceous gout can cause permanent joint damage, nerve compression, and spinal cord compression if tophi develop around the spine. Renal urate nephropathy — chronic damage to kidney tubules from uric acid deposition — can progress quietly over years. These are preventable consequences of untreated hyperuricemia. Starting and maintaining effective ULT reverses tophi over 12–24 months and prevents these outcomes.
Frequently Asked Questions
An acute gout flare will typically resolve on its own within 7–14 days even without treatment, because the body gradually reabsorbs the uric acid crystals. But "it goes away" does not mean it should be left alone. Without treatment, flares become more frequent, last longer, and affect more joints over time. Joint damage accumulates silently between attacks. Treatment during an acute flare shortens pain duration significantly, and long-term urate-lowering therapy prevents recurrence and joint destruction.
No. Diet is a contributing factor, but it is rarely the sole cause. The body produces about two-thirds of its uric acid internally through normal cell turnover. Genetics plays a large role — many patients have an inherited tendency toward either overproducing uric acid or underexcreting it through the kidneys. Chronic kidney disease, certain blood pressure medications (especially thiazide diuretics), and obesity are among the most common drivers. Diet adjustments help, but they typically lower serum uric acid by only 1–2 mg/dL — not enough on their own to reach the treatment target of under 6 mg/dL in most patients.
No — and this is one of the most common mistakes I see. If you are already taking allopurinol or febuxostat and you develop a flare, continue your medication. Stopping urate-lowering therapy causes uric acid levels to swing back upward, which can worsen or prolong the current flare and trigger additional ones. The 2020 ACR guidelines explicitly recommend continuing existing ULT during flares.[1] Add colchicine, an NSAID, or a short steroid course to treat the flare itself.
This confuses patients and clinicians alike. During an acute flare, uric acid shifts from the blood into the inflamed joint, so a blood test drawn at that moment may show a normal or even low serum uric acid level. A normal result during a flare does not rule out gout. For an accurate baseline uric acid level, blood should ideally be drawn at least two to four weeks after the acute flare resolves.[4]
For most patients, allopurinol is a long-term — often lifelong — medication. Gout is a chronic disease driven by urate crystal deposition in tissues. Stopping allopurinol causes uric acid to rise again, and crystals re-accumulate. The 2020 ACR guidelines recommend indefinite ULT for patients with tophaceous gout, radiographic joint damage, or frequent flares. Some patients with a single flare and no comorbidities may eventually discuss discontinuation with their physician after sustained uric acid control, but this is the exception rather than the rule.
Cherries and cherry extract have genuine — if modest — evidence behind them. Several observational studies have found an association between cherry consumption and reduced gout flare frequency. Cherries contain anthocyanins that may inhibit uric acid production and reduce inflammation. The 2020 ACR guidelines conditionally recommend cherry consumption as part of dietary management.[1] They are not a substitute for urate-lowering therapy, but adding cherries or tart cherry extract is a reasonable, low-risk adjunct alongside medical treatment.
References
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research. 2020;72(6):744–760. https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24180
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 ACR Guideline for Management of Gout (PubMed). Arthritis Care & Research. 2020. https://pubmed.ncbi.nlm.nih.gov/32391934/
- Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study (AGREE trial). Arthritis & Rheumatism. 2010;62(4):1060–1068. https://onlinelibrary.wiley.com/doi/10.1002/art.27327
- Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Annals of the Rheumatic Diseases. 2015;74(10):1789–1798. https://ard.bmj.com/content/74/10/1789
- Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. The Lancet. 2020;396(10264):1745–1757. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01385-4/fulltext
- Jamnik J, Rehman S, Blanco Mejia S, et al. Fructose intake and risk of gout and hyperuricemia: a systematic review and meta-analysis of prospective cohort studies. BMJ Open. 2016;6(10):e013191. https://pmc.ncbi.nlm.nih.gov/articles/PMC5073537/
- Rheumatology Advisor. No Difference Between Early and Late Allopurinol Initiation for Acute Gout Flare. 2021. https://www.rheumatologyadvisor.com/news/no-difference-between-early-and-late-allopurinol-initiation-for-acute-gout-flare/
- National Institute for Health and Care Excellence. Evidence reviews for timing of urate-lowering therapy in relation to a gout flare. 2022. https://www.ncbi.nlm.nih.gov/books/NBK583523/